| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 9 | 40 | +0,90 % | ||
| ZEALAND PHARMA | 5 | 1 | +2,12 % | ||
| VESTAS WIND SYSTEMS | 3 | 9 | -0,70 % | ||
| AP MOELLER-MAERSK | 1 | 23 | +1,19 % | ||
| TRYG | 1 | - | -2,97 % | ||
| ORSTED | - | 17 | -1,02 % | ||
| DANSKE BANK | - | 10 | +0,12 % | ||
| BAVARIAN NORDIC | - | 7 | -0,16 % | ||
| DSV | - | 4 | +0,27 % | ||
| ROCKWOOL | - | 4 | -2,58 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:30 | KURSZIEL ANGEHOBEN bei Novo nordisk: Was Insider heute bereits wissen - Meine klare Einschätzung dazu | Hebelschein-Spekulant | |||
| 15:34 | Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth? | 22 | Zacks | ||
| 14:10 | Novo Nordisk A/S: Novo Nordisk to present new data on Wegovy, women with obesity and next-generation weight loss treatments at European Congress on Obesity | 1.477 | GlobeNewswire (Europe) | Analyses of the higher dose of Wegovy (semaglutide 7.2 mg) and Wegovy pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achievedWegovy... ► Artikel lesen | |
| 13:39 | NOVO NORDISK A/S - Stabilität mit strategischer Tiefe | 18 | Maximilian Berger | ||
| 13:00 | Tryg A/S: Tryg recognises a one-off impact of DKK 1.2bn pre-tax related to Supreme Court ruling on Danish workers' compensation | 113 | GlobeNewswire (Europe) | Today, the Danish Supreme Court ruled on a precedent-setting case regarding workers' compensation in Denmark, which affects the entire insurance industry as well as the State and municipalities in Denmark.... ► Artikel lesen | |
| 10:27 | Is This Deal a Game Changer for Novo Nordisk? | 76 | The Motley Fool | ||
| 08:22 | Erfolg in Phase-3-Studie: Survodutid von Zealand Pharma erzielt 16,6 % Gewichtsverlust | 11 | Investing.com Deutsch | ||
| 08:22 | Zealand Pharma: Survodutide erzielt 16,6 % Gewichtsverlust in Phase-III-Studie | 17 | Investing.com Deutsch | ||
| 08:18 | Zealand Pharma's survodutide shows 16.6% weight loss in trial | 5 | Investing.com | ||
| 08:18 | Zealand Pharma's survodutide achieves 16.6% weight loss in trial | 3 | Investing.com | ||
| 08:06 | Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial | 332 | GlobeNewswire (Europe) | Company announcement - No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic... ► Artikel lesen | |
| 03:06 | Central Vietnam hub Danang deepens cooperation with Maersk on Lien Chieu port, logistics | 2 | Theinvestor.vn | ||
| Mo | Prothena Corporation plc: Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy | 419 | Business Wire |
Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3
Coramitug is being evaluated by Novo Nordisk in the ongoing Phase... ► Artikel lesen | |
| Mo | Maersk lines up Med-Baltic SLA loop from Tanger Med | 4 | PortNews | ||
| Mo | Vestas wins 186MW Quebec turbine order | 9 | reNews | ||
| Mo | A.P. Møller - Mærsk A/S: Transactions in connection with share buy-back program | 2 | GlobeNewswire (USA) | ||
| Mo | Vestas stärkt Präsenz in Nord Amerika | 5 | Windkraft-Journal | ||
| Mo | VESTAS WIND SYSTEMS A/S: Vestas strengthens Québec presence with 186 MW order from EDF power solutions North America | 6 | Cision News | ||
| Mo | Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet? | 68 | Zacks | ||
| Mo | Maersk reshapes Asia-Europe network with port swaps and new calls from April 2026 | 3 | PortNews |